BeOne Medicines (ONC) Other financing activities (2016 - 2026)

BeOne Medicines (ONC) has reported Other financing activities for 11 consecutive years, with $23.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities fell 62.32% year-over-year to $23.9 million; the TTM figure through Mar 2026 stood at $156.8 million (up 204.06% YoY), while the FY2025 annual figure was $196.3 million, up 6442.7% from the prior year.
• Other financing activities declined to $23.9 million in Q1 2026 per ONC's latest filing, from $196.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $196.3 million in Q4 2025 and bottomed at -$63.4 million in Q2 2025.
• Historically, Other financing activities has averaged $13.9 million across 5 years, with a median of $13.3 million in 2022.
• Annual changes were most pronounced in 2023 — Other financing activities plunged 545.42% — and 2025, when it soared 684.55%.
• BeOne Medicines' Other financing activities stood at -$35.7 million in 2022, then tumbled by 46.74% to -$52.4 million in 2023, then soared by 35.86% to -$33.6 million in 2024, then jumped by 684.55% to $196.3 million in 2025, then tumbled by 87.84% to $23.9 million in 2026.
• Business Quant data shows ONC's Other financing activities at $23.9 million in Q1 2026, $196.3 million in Q4 2025, and -$63.4 million in Q2 2025.